Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and New

被引:20
|
作者
Mackenzie, Samuel J. [1 ,2 ]
Nicolau, Stefan [1 ]
Connolly, Anne M. [1 ,2 ]
Mendell, Jerry R. [1 ,2 ]
机构
[1] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH 43205 USA
[2] Ohio State Univ, Dept Pediat & Neurol, Columbus, OH 43210 USA
关键词
NATURAL-HISTORY; DOUBLE-BLIND; MUSCLE FUNCTION; MOUSE MODEL; DMD; PREDNISONE; TRIAL; GENE; EXPRESSION; SKELETAL;
D O I
10.1016/j.spen.2021.100877
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Duchenne muscular dystrophy (DMD) is marked by pathogenic variants in the DMD gene, leading to reduced or absent dystrophin translation, muscle fiber destruction, loss of ambulation, cardiomyopathy, respiratory failure, and eventually death. Disease progression is slowed with use of prednisone or other corticosteroid agents. Gene replacement therapy, which is one of the focus points of this review, has emerged as the most promising potential treatment for DMD, though alternative RNA-based strategies have been employed for patients with specific pathogenic variants. While challenges remain, many of these novel therapeutic approaches hold promise for treating this devastating disease. (C) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy
    Happi Mbakam, Cedric
    Lamothe, Gabriel
    Tremblay, Jacques P.
    [J]. FRONTIERS IN MEDICINE, 2022, 9
  • [42] THERAPEUTIC TRIAL OF ISAXONINE IN DUCHENNE MUSCULAR-DYSTROPHY
    HECKMATT, JZ
    HYDE, SA
    GABAIN, A
    DUBOWITZ, V
    [J]. MUSCLE & NERVE, 1988, 11 (08) : 836 - 847
  • [43] Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy
    Krishna, Lakshmi
    Prashant, Akila
    Kumar, Yogish H.
    Paneyala, Shasthara
    Patil, Siddaramappa J.
    Ramachandra, Shobha Chikkavaddaragudi
    Vishwanath, Prashant
    [J]. NEUROLOGY INTERNATIONAL, 2024, 16 (04): : 731 - 760
  • [44] Molecular Therapeutic Strategies Targeting Duchenne Muscular Dystrophy
    Mendell, Jerry R.
    Rodino-Klapac, Louise R.
    Malik, Vinod
    [J]. JOURNAL OF CHILD NEUROLOGY, 2010, 25 (09) : 1145 - 1148
  • [45] Duchenne muscular dystrophy: Current state and therapeutic perspectives
    Le Guen, Y. T.
    Le Gall, T.
    Laurent, V
    D'Arbonneau, F.
    Braun, S.
    Montier, T.
    [J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2021, 205 (05): : 509 - 518
  • [46] Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy
    Eleonora S. D’Ambrosio
    Jerry R. Mendell
    [J]. Neurotherapeutics, 2023, 20 : 1669 - 1681
  • [47] Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy
    Vianello, Sara
    Yu, Hua
    Voisin, Vincent
    Haddad, Hafedh
    He, Xun
    Foutz, Arthur S.
    Sebrie, Catherine
    Gillet, Brigitte
    Roulot, Morgane
    Fougerousse, Francoise
    Perronnet, Caroline
    Vaillend, Cyrille
    Matecki, Stefan
    Escolar, Diana
    Bossi, Laura
    Israel, Maurice
    de la Porte, Sabine
    [J]. FASEB JOURNAL, 2013, 27 (06): : 2256 - 2269
  • [48] Potential Therapeutic Action of Adiponectin in Duchenne Muscular Dystrophy
    Abou-Samra, Michel.
    Boursereau, Raphael
    Lecompte, Sophie
    Noel, Laurence
    Brichard, Sonia M.
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2017, 187 (07): : 1577 - 1585
  • [49] Advances in genetic therapeutic strategies for Duchenne muscular dystrophy
    Guiraud, Simon
    Chen, Huijia
    Burns, David T.
    Davies, Kay E.
    [J]. EXPERIMENTAL PHYSIOLOGY, 2015, 100 (12) : 1458 - 1467
  • [50] Potential therapeutic targets for hypotension in duchenne muscular dystrophy
    Saxena, Harshi
    Weintraub, Neal L.
    Tang, Yaoliang
    [J]. MEDICAL HYPOTHESES, 2024, 185